Literature DB >> 15107868

Provision of rheumatology services in New Zealand.

Andrew Harrison1.   

Abstract

AIMS: To measure equity of access to rheumatology services and to assess the adequacy of the rheumatology workforce-compared with published recommended levels, United Kingdom levels, and previous New Zealand data; and to provide data to assist in workforce planning.
METHODS: Data from of the central North Island of New Zealand were obtained during a review of rheumatology services in the Midland region. Complete national public-sector rheumatology workforce data were obtained in a separate survey.
RESULTS: This study demonstrates wide geographical variation in outpatient (more than three-fold variation) and inpatient (more than six-fold variation) service volumes per capita between the District Health Boards of the Midland region. Outpatient waiting lists were not higher in underserviced areas. Nationally, there were 251,211 people for each full time equivalent (FTE) rheumatologist, compared with the 1999 level of 235,593 population per FTE, and well behind the UK recommendation of 85,000 people per FTE. CONCLUSIONS This study has demonstrated marked variation in access to rheumatology services based on geographical location, as well as evidence of a worsening shortage of rheumatologists in New Zealand.

Entities:  

Mesh:

Year:  2004        PMID: 15107868

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  2 in total

1.  An update on UK rheumatology consultant workforce provision: the BSR/ARC Workforce Register 2005-07: assessing the impact of recent changes in NHS provision.

Authors:  M J Harrison; C Deighton; D P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2008-04-18       Impact factor: 7.580

2.  Apps for People With Rheumatoid Arthritis to Monitor Their Disease Activity: A Review of Apps for Best Practice and Quality.

Authors:  Rebecca Grainger; Hermaleigh Townsley; Bonnie White; Tobias Langlotz; William J Taylor
Journal:  JMIR Mhealth Uhealth       Date:  2017-02-21       Impact factor: 4.773

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.